One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast ...

CAR T-cell therapy, which uses genetically enhanced versions of a patient's own cancer-fighting T-cells, is revolutionizing ...

One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast ...

T-cells are real life saviors. If modified properly, they can save lupus patients from the trouble of taking medicines ...

Researchers developed SNIPRs, innovative receptors that sense soluble ligands, enabling precise therapeutic control in CAR ...

UCSF researchers develop customizable SNIPR sensors that activate engineered cells only near tumors, promising precise cancer ...

Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window ...

Researchers have developed an innovative CAR T-cell therapy to combat glioblastoma, the most common malignant brain tumor in ...

Dolores Schendel, Chief Scientific Officer and Kirsty Crame, MD, Vice President, Clinical Strategy & Development Presentations and seminars highlighted Medigene’s proprietary End-to-End Platform for ...

T therapy targeting p95HER2 shows complete and durable tumor responses in HER2+ breast cancer preclinical models. Combining ...

Obe-cel was designed to increase T-cell persistence and reduce T-cell exhaustion and was shown to improve response rates and survival, particularly in patients with low leukemia burden.

Blocking a protein that imports lactic acid, a metabolic byproduct of cancer cells, reinvigorated exhausted T cells and led ...